Perspective Therapeutics (CATX) Stock Forecast & Price Target

$3.21 -0.01 (-0.31%)

Closing price 08/18/2026 04:10 PM Eastern

Extended Trading

$3.26 +0.05 (+1.62%)

As of 07:00 AM Eastern

Compare

Perspective Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Perspective Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for CATX.

Consensus Price Target

$11.50
258.26% Upside

According to the 9 analysts' twelve-month price targets for Perspective Therapeutics, the average price target is $11.50. The highest price target for CATX is $14.00, while the lowest price target for CATX is $5.00. The average price target represents a forecasted upside of 258.26% from the current price of $3.21.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CATX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Perspective Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CATX Analyst Ratings Over Time

Type	Current Forecast 8/19/25 to 8/19/26	1 Month Ago 7/20/25 to 7/20/26	3 Months Ago 5/21/25 to 5/21/26	1 Year Ago 8/19/24 to 8/19/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.50	$12.63	$12.63	$12.56
Forecasted Upside	258.26% Upside	332.36% Upside	226.23% Upside	267.12% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Buy

CATX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CATX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Perspective Therapeutics Stock vs. The Competition

Type	Perspective Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.89	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	258.26% Upside	799.42% Upside	12.58% Upside
News Sentiment Rating	Positive News See Recent CATX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/18/2026	BMO Capital Markets 3 of 5 stars		Set Target		$11.00	+242.68%
8/14/2026	Bank of America 4 of 5 stars	Alec Stranahan Not Rated	Lower Target	Neutral	$6.00 ➝ $5.00	+56.49%
8/11/2026	Piper Sandler 2 of 5 stars	Biren Amin 5 of 5 stars	Lower Target	Overweight	$16.00 ➝ $14.00	+366.67%
7/24/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeet Mukherjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
5/5/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$11.00	+190.93%
3/23/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$12.00 ➝ $13.00	+192.13%
3/18/2026	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yuan Zhi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$11.00 ➝ $13.00	+164.66%
3/18/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Dai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$7.00 ➝ $8.00	+61.62%
3/17/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$12.00	+135.52%
3/17/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$18.00 ➝ $14.00	+186.83%
Ready to give options a try? Your first trade (Ticker included) -INSIDE (Ad) Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.
7/12/2025	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00	+455.55%
3/4/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Li Watsek Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
11/22/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$22.00 ➝ $16.00	+433.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:01 AM ET.

CATX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Perspective Therapeutics is $11.50, with a high forecast of $14.00 and a low forecast of $5.00.

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CATX shares.

According to analysts, Perspective Therapeutics's stock has a predicted upside of 258.26% based on their 12-month stock forecasts.

Perspective Therapeutics has been rated by research analysts at Bank of America, BMO Capital Markets, BTIG Research, and Piper Sandler in the past 90 days.

Analysts like Perspective Therapeutics more than other "healthcare" companies. The consensus rating for Perspective Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CATX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Perspective Therapeutics Recommendations

This page (NYSEAMERICAN:CATX) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perspective Therapeutics (CATX) Stock Forecast & Price Target

Perspective Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

CATX Analyst Ratings Over Time

CATX Analyst Recommendations By Month

CATX Price Targets by Month

Perspective Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

CATX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Perspective Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perspective Therapeutics (CATX) Stock Forecast & Price Target

Perspective Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

CATX Analyst Ratings Over Time

CATX Analyst Recommendations By Month

CATX Price Targets by Month

Perspective Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

CATX Forecast - Frequently Asked Questions

What is Perspective Therapeutics' forecast for 2026?

Should I buy or sell Perspective Therapeutics stock right now?

Does Perspective Therapeutics's stock price have much upside?

What analysts cover Perspective Therapeutics?

Do Wall Street analysts like Perspective Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Perspective Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools